INDAPTUS THERAPEUTICS INC (INDP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.16+5.69%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge INDAPTUS THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.52
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-6.34
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-4.42

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Stabilize senior management team to support execution	A supporting condition in INDAPTUS THERAPEUTICS INC's published investment case. The stated target is no further major senior executive departures in next 4 quarters.	Under Pressure	additional senior executive resignations occur	1 director departure vs 0 senior executive departures target Director Tim Ruan resigned on 2026-09-04. No senior executive departures reported in recent news. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage net losses to avoid worsening financial health	Indaptus aims to manage cash flow despite net losses near -$8.11M in 2025-Q4.	Broken	net losses worsen beyond -$8.11M in any quarter	Net income: $-1.795M FY2026-Q2; GAAP. Published target: net losses do not worsen beyond -$8.11M in next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-1,794,863 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f300769d-21d4-4d62-83a1-f6c0ab4b34d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize cash from operations to sustain operations	Indaptus aims to manage cash flow despite net losses near -$8.11M in 2025-Q4.	Broken	cash from operations worsens beyond -$7.01M in any quarter	Cash from operations: $-1.928M FY2026-Q2; GAAP. Published target: cash from operations does not decline further beyond -$7.01M in next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 13, 2026-1,927,634 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-07	Unavailable	Unavailable	1 / 0
2026-08-08	Unavailable	Unavailable	1 / 0
2026-08-09	Unavailable	Unavailable	1 / 1
2026-08-10	Unavailable	Unavailable	1 / 1
2026-08-12	Unavailable	Unavailable	1 / 0
2026-08-13	Unavailable	Unavailable	1 / 1
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	1 / 0
2026-09-26	Unavailable	Unavailable	1 / 0
2026-09-27	Unavailable	Unavailable	1 / 0
2026-09-28	Unavailable	Unavailable	1 / 0
2026-09-29	Unavailable	Unavailable	1 / 0
2026-09-30	Unavailable	Unavailable	1 / 0
2026-10-01	Unavailable	Unavailable	1 / 0
2026-10-02	Unavailable	Unavailable	1 / 0
2026-10-03	Unavailable	Unavailable	1 / 0
2026-10-04	Unavailable	Unavailable	1 / 0
2026-10-05	Unavailable	Unavailable	1 / 0
2026-10-06	Unavailable	Unavailable	1 / 0
2026-10-07	Unavailable	Unavailable	1 / 0
2026-10-08	Unavailable	Unavailable	1 / 0
2026-10-09	Unavailable	Unavailable	1 / 0
2026-10-10	Unavailable	Unavailable	1 / 0
2026-10-11	Unavailable	Unavailable	1 / 0
2026-10-12	Unavailable	Unavailable	1 / 0
2026-10-13	Unavailable	Unavailable	1 / 0
2026-10-14	Unavailable	Unavailable	1 / 0
2026-10-15	Unavailable	Unavailable	1 / 0
2026-10-16	Unavailable	Unavailable	1 / 0
2026-10-17	Unavailable	Unavailable	1 / 0
2026-10-18	Unavailable	Unavailable	1 / 0
2026-10-19	Unavailable	Unavailable	1 / 0
2026-10-20	Unavailable	Unavailable	1 / 0
2026-10-21	Unavailable	Unavailable	1 / 0
2026-10-22	Unavailable	Unavailable	1 / 0
2026-10-23	Unavailable	Unavailable	1 / 0
2026-10-24	Unavailable	Unavailable	1 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Monthly analyst history is unavailable.

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stabilize senior management team to support executionPublished status: Under Pressure
Manage net losses to avoid worsening financial healthPublished status: Broken
Stabilize cash from operations to sustain operationsPublished status: Broken

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

5.7%Typical daily move · historical

Downside history

-80.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

INDAPTUS THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, loss-making biotechnology business rather than an established earnings compounder. The long-term thesis is intact in the snapshot, but confidence is low and depends on strategic alternatives, research collaborations, and leadership transition.

What's priced into INDAPTUS THERAPEUTICS INC

The evidence does not provide a valuation measure or a clear account of market expectations, so whether INDP is cheap, fair, or expensive cannot be assessed. Recent price reaction is described as muted, but that alone does not show what the market assumes.

What the fundamentals likely do

Near term, management is winding down Decoy20 enrollment, has no active clinical programs, and is evaluating alternatives while reducing expenses. A private placement lifted cash and short-term investments from the prior quarter, but the company remains loss-making and recently missed a quarter amid erratic earnings surprises, creating elevated next-quarter risk.

What INDAPTUS THERAPEUTICS INC hinges on

Over the multi-year view, the key swing factor is whether management finds a strategic path or research collaborations that can support the business after the clinical wind-down. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness from healthcare bellwethers may reinforce or fade the sector tailwind.